{"title":"Prospects and perils of ChatGPT in diabetes.","authors":"Gumpeny R Sridhar, Lakshmi Gumpeny","doi":"10.4239/wjd.v16.i3.98408","DOIUrl":null,"url":null,"abstract":"<p><p>ChatGPT, a popular large language model developed by OpenAI, has the potential to transform the management of diabetes mellitus. It is a conversational artificial intelligence model trained on extensive datasets, although not specifically health-related. The development and core components of ChatGPT include neural networks and machine learning. Since the current model is not yet developed on diabetes-related datasets, it has limitations such as the risk of inaccuracies and the need for human supervision. Nevertheless, it has the potential to aid in patient engagement, medical education, and clinical decision support. In diabetes management, it can contribute to patient education, personalized dietary guidelines, and providing emotional support. Specifically, it is being tested in clinical scenarios such as assessment of obesity, screening for diabetic retinopathy, and provision of guidelines for the management of diabetic ketoacidosis. Ethical and legal considerations are essential before ChatGPT can be integrated into healthcare. Potential concerns relate to data privacy, accuracy of responses, and maintenance of the patient-doctor relationship. Ultimately, while ChatGPT and large language models hold immense potential to revolutionize diabetes care, one needs to weigh their limitations, ethical implications, and the need for human supervision. The integration promises a future of proactive, personalized, and patient-centric care in diabetes management.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 3","pages":"98408"},"PeriodicalIF":4.2000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885976/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4239/wjd.v16.i3.98408","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
ChatGPT, a popular large language model developed by OpenAI, has the potential to transform the management of diabetes mellitus. It is a conversational artificial intelligence model trained on extensive datasets, although not specifically health-related. The development and core components of ChatGPT include neural networks and machine learning. Since the current model is not yet developed on diabetes-related datasets, it has limitations such as the risk of inaccuracies and the need for human supervision. Nevertheless, it has the potential to aid in patient engagement, medical education, and clinical decision support. In diabetes management, it can contribute to patient education, personalized dietary guidelines, and providing emotional support. Specifically, it is being tested in clinical scenarios such as assessment of obesity, screening for diabetic retinopathy, and provision of guidelines for the management of diabetic ketoacidosis. Ethical and legal considerations are essential before ChatGPT can be integrated into healthcare. Potential concerns relate to data privacy, accuracy of responses, and maintenance of the patient-doctor relationship. Ultimately, while ChatGPT and large language models hold immense potential to revolutionize diabetes care, one needs to weigh their limitations, ethical implications, and the need for human supervision. The integration promises a future of proactive, personalized, and patient-centric care in diabetes management.
期刊介绍:
The WJD is a high-quality, peer reviewed, open-access journal. The primary task of WJD is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of diabetes. In order to promote productive academic communication, the peer review process for the WJD is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJD are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in diabetes. Scope: Diabetes Complications, Experimental Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes, Gestational, Diabetic Angiopathies, Diabetic Cardiomyopathies, Diabetic Coma, Diabetic Ketoacidosis, Diabetic Nephropathies, Diabetic Neuropathies, Donohue Syndrome, Fetal Macrosomia, and Prediabetic State.